Browse

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy

DC Field Value Language
dc.contributor.authorLee, Jae Jin-
dc.contributor.authorKim, Tae Min-
dc.contributor.authorYu, Su Jong-
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorJoh, Yo-han-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorKwon, Jung Hye-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorKim, Noe Kyeong-
dc.date.accessioned2020-04-27T11:46:46Z-
dc.date.available2020-04-27T11:46:46Z-
dc.date.issued2004-07-
dc.identifier.citationJapanese Journal of Clinical Oncology, Vol.34 No.7, pp.400-404-
dc.identifier.issn0368-2811-
dc.identifier.other95326-
dc.identifier.urihttps://hdl.handle.net/10371/165572-
dc.description.abstractObjective: The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%). However, its efficacy in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin (5-FU/LV) has not been determined. This study was performed to evaluate the efficacy and to identify the side-effects of capecitabine in patients with metastatic colorectal cancer showing progression despite 5-FU/LV-based combination chemotherapy. Methods: Fifty-one metastatic colorectal cancer patients who showed progressive disease in 5-FU/LV-containing regimens (median: two regimes) were treated with capecitabine 1250 mg/m(2) twice daily (days 1-14 repeated every 3 weeks). Results: Only one partial response was observed (response rate: 2%). Twenty-seven patients (53%) showed stable disease after two cycles. The median time to disease progression of either a partial response or stable disease was 3.4 months. Hand-foot syndrome was the main toxicity of capecitabine and occurred in 35% of cases (grade 3 or 4 in 6%). The median number of cycles administered was two and the relative dose intensity of capecitabine was 80%. Conclusion: The response rate to capecitabine was low in metastatic colorectal cancers that were refractory to 5-FU/LV-containing chemotherapy. However, disease stabilization was seen in a significant number of patients.-
dc.subjectcapecitabine-
dc.subjectmetastatic colorectal-
dc.subjectcancer-
dc.subjectsecond-line chemotherapy-
dc.titleSingle-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1093/jjco/hyh068-
dc.citation.journaltitleJapanese Journal of Clinical Oncology-
dc.identifier.scopusid2-s2.0-6044243224-
dc.citation.endpage404-
dc.citation.number7-
dc.citation.startpage400-
dc.citation.volume34-
dc.identifier.urlhttps://academic.oup.com/jjco/article/34/7/400/815667-
dc.identifier.rimsid95326-
dc.identifier.sci000224504300005-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorKim, Dong-Wan-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse